Side Effects and Hazards of Biologics: Quality Risks from the Perspectives of Immunogenicity and Manufacturing Processes

Immunogenicity: A Potential Safety Hazard of Biological Products

Biological products are mostly derived from living cell expression systems, with relatively complex molecular structures, and may contain host cell proteins, post-translational modification differences, and other factors. The human immune system may recognize certain components of the drug as foreign substances, thereby producing anti-drug antibodies. The emergence of anti-drug antibodies may affect drug efficacy and may also lead to allergic reactions, serum sickness-like reactions, or infusion-related reactions. The immunogenicity risk varies among different products, and manufacturing processes, formulation, route of administration, and individual patient status can all affect the probability of immunogenicity.

Although immunogenicity does not necessarily lead to obvious clinical consequences, continuous monitoring of anti-drug antibody levels helps evaluate long-term safety. During the research and development stage, immunogenicity risk is usually preliminarily assessed through in vitro experiments and animal models. After marketing, safety information still needs to be continuously supplemented through real-world data.

Impacts of Process-Related Impurities and Formulation Excipients

Impurities such as host cell DNA, host cell proteins, Protein A, and endotoxins may remain during the production process. If these impurities exceed quality control limits, they may induce fever, inflammatory reactions, or allergic reactions. In common specifications and general requirements, strict limits are set for the residual amounts of the above impurities, and companies need to demonstrate product consistency through purification processes and multi-batch testing.

Excipients in formulations such as polysorbates, histidine, and sucrose may also cause intolerance or allergy in a small number of people. In addition, biological products are relatively sensitive to temperature, light, and mechanical stress. Improper storage and transportation may lead to protein aggregation or degradation, increasing the risk of immunogenicity. Therefore, cold chain management and stability studies are important links in ensuring quality.

Quality Standards and Full Lifecycle Risk Control

Quality control of biological products runs through the entire process of research and development, production, distribution, and use. The production process should follow Good Manufacturing Practices for Drugs, and key raw materials, cell banks, purification processes, and analytical methods should be validated. Quality standards generally include appearance, pH, protein content, purity, biological activity, sterility, endotoxins, visible particulates, and other items. Different products will add specific test items according to product characteristics.

After marketing, companies also need to carry out pharmacovigilance activities, collect adverse reaction reports, evaluate risk signals, and update instructions or risk control plans when necessary. Regulatory agencies will also conduct regular inspections of biological product manufacturing sites to ensure the continuous stability of the quality system. Through strict production control and full lifecycle risk management, the probability of side effects and harms of biological products can be reduced to a certain extent, ensuring patient medication safety.